Navigation Links
Arteriocyte Receives FDA Approval to Move Forward with Critical Limb Ischemia Trial
Date:1/28/2011

CLEVELAND, Jan. 28, 2011 /PRNewswire-USNewswire/ -- Arteriocyte®, a leading clinical stage biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts that develops proprietary stem cell and tissue engineering based therapies, announced today approval from the Food and Drug Administration (FDA) to initiate a Phase I clinical trial using its Magellan MAR01™ technology in the treatment of Critical Limb Ischemia (CLI). The FDA Investigational Device Exemption (IDE 14522) allows Arteriocyte and its clinical partners to initiate evaluation of concentrated marrow injections (using the Magellan MAR01™ technology) in improving perfusion in ischemic tissue in affected limbs of patients with CLI who are not eligible for revascularization surgery.

(Logo: http://photos.prnewswire.com/prnh/20100624/ALOGO)

The Magellan technology combines a rapid bedside tissue concentration device and sterile surgical disposables that produce platelet rich plasma from blood and bone marrow aspirations in approximately 15 minutes and was FDA approved through the 510(k) process for use as deemed appropriate by surgeons. The Magellan MAR01™ technology enables the rapid "closed system" concentration of aspirated bone marrow, yielding an injectable tissue rich in platelets, hematopoietic stem cells and mesenchymal stem cells, commonly viewed as key components in tissue repair. The company is developing MAR01™ for use as a clinical treatment for Critical Limb Ischemia, and plans to initiate additional clinical trials evaluating MAR01™ in cardiovascular disease, and the clinical setting of orthopedics and tissue repair during 2011.

Patient enrollment for the phase I safety study will begin immediately at The Ohio State University Medical Center (as the first clinical site), under the direction of Dr. Michael Go, Assistant Professor of Surgery in the Division
'/>"/>

SOURCE Arteriocyte, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arteriocyte Named Top Biotech Start Up Venture by the Ohio Venture Association for 2010
2. 3SBio Inc. Receives SFDA Approval for TPIAO Label Extension for the Treatment of ITP
3. Soligenix Receives FDA Orphan Drug Designation for RiVax™ for the Prevention of Ricin Intoxication
4. Regenicin Receives Positive Feedback at OneMedForum Conference
5. Neogens Rapid Test for Salmonella enteritidis Receives FDA Approval
6. Regenicin COO Receives Citizenship Award from VFW Post 1 in Colorado
7. Foundation Venture Capital Group Company Receives $8.2 Million DoD Contract
8. Teysuno™ (S-1) Receives CHMP Positive Opinion for Approval as First-Line Therapy for Advanced Gastric Cancer
9. Quest Diagnostics® Care360™ EHR Receives ONC-ATCB 2011/2012 Certification
10. Pittsburgh-based BIOSAFE Receives EPA Registration and Enters Into Commercialization Agreement with Union Springs Pharmaceuticals
11. PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... (PRWEB) October 20, 2014 Convey ... that a team from Iowa State University won first ... contest. Using a Convey HC-2ex, the team’s solution achieved ... times faster than the second place finisher. , Experts ... embarked upon the month long challenge, using a variety ...
(Date:10/20/2014)... , Oct. 20, 2014  GenVec, Inc. (NASDAQ: ... P. Horovitz , Ph.D., from its board of directors effective ... in August 2003, and served as its chairman from June ... on the Nominating and Corporate Governance and Audit Committees of ... more than a decade of dedicated service to GenVec, and ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Local veterinary ... in an investigational study of donor stem cells for ... stem cell therapy and has performed clinical stem cell ... study is to determine if a single injection of ... joints can help reduce pain and inflammation in the ...
(Date:10/19/2014)... 19, 2014 The Asia-Pacific Bromine ... in Asia-Pacific with analysis and forecast of revenue. ... Pacific Bromine Market report, to get an idea ... a glimpse of the segmentation in the Asia-Pacific ... and figures. , http://www.micromarketmonitor.com/market/asia-pacific-bromine-6741503144.html , ...
Breaking Biology Technology:Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Zola P. Horovitz To Retire From GenVec Board 2Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 3
... to $14.8 Million ... ... MINNEAPOLIS, May 5 ATS Medical, Inc. (Nasdaq:,ATSI), manufacturer and ... for the first,quarter ended March 29, 2008. Revenue for the quarter ...
... 5 Assay Designs, Inc., a leading,provider of ... sciences,and translational research markets, announced a collaboration on ... of South Carolina and,Dr. Jennifer Isaacs, laboratory. Under ... anti-Heat shock protein 90 (Hsp90) antibody for both,cell-based ...
... 5 NorthPoint Domain, an IC Sciences,company, announced ... at NYU Langone Medical Center to develop a ... care delivery.,Based on a shared commitment to excellence ... to provide clinicians with new,tools to inform, engage, ...
Cached Biology Technology:ATS Medical Announces Record Quarterly Revenue and Gross Profit 2ATS Medical Announces Record Quarterly Revenue and Gross Profit 3ATS Medical Announces Record Quarterly Revenue and Gross Profit 4ATS Medical Announces Record Quarterly Revenue and Gross Profit 5ATS Medical Announces Record Quarterly Revenue and Gross Profit 6ATS Medical Announces Record Quarterly Revenue and Gross Profit 7ATS Medical Announces Record Quarterly Revenue and Gross Profit 8ATS Medical Announces Record Quarterly Revenue and Gross Profit 9Assay Designs(TM) Announces Collaboration with Medical University of South Carolina (MUSC) 2NorthPoint Domain and NYU Vascular Associates Partner to Develop New Generation of Care Delivery Informatics Instruments 2NorthPoint Domain and NYU Vascular Associates Partner to Develop New Generation of Care Delivery Informatics Instruments 3
(Date:10/16/2014)... Institute of Marine Science have received a 3-year, ... identify the streams and wetlands most vulnerable to ... local governments and citizens conserve these important ecosystems. ... of tidal-marsh observations first gathered by VIMS scientists ... can today,s researchers accurately map the slow but ...
(Date:10/16/2014)... women experienced improvements in vaginal atrophy, with no ... after 12 weeks of daily 10 milligram (mg) ... supplement previously shown to help relieve certain menopause ... reported in a poster at the North American ... "These data documented improved vaginal epithelium, without significant ...
(Date:10/15/2014)... admitted Johannes Gutenberg University Mainz (JGU) as a ... continues to maintain a significant nationwide standing in ... acceptance of Johannes Gutenberg University Mainz as a ... in the national and international competition for the ... Rhineland-Palatinate can be proud that Mainz University has ...
Breaking Biology News(10 mins):EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3
... of a novel class of mutations that disrupt the function ... mutation created the appearance of an "illegitimate" microRNA (miRNA) recognition ... its normal form. In this study, the gene concerned ... muscle and the function of the derived protein is to ...
... it's rice farming or rice research, very few of Asia's ... in an industry that has been a foundation of the ... their children to be rice farmers, and even fewer young ... importance to the region. , However, an innovative project ...
... million people in sub-Saharan Africa, according to the World ... the virus have achieved limited success. But what if ... in that region of Africa ?chancroid ?was relatively easy ... much as 10-fold? , That may be the case, ...
Cached Biology News:A rice future for Asia 2Vaccine shown effective against chancroid 2Vaccine shown effective against chancroid 3
... modified nucleotide structure called a ?cap? ... most naturally-occurring eukaryotic mRNAs and many ... for a portion of the GTP ... reaction results in the synthesis of ...
... A modified nucleotide structure called a ... of most naturally-occurring eukaryotic mRNAs and ... Analog for a portion of the ... transcription reaction results in the synthesis ...
... A modified nucleotide structure called ... 5?-end of most naturally-occurring eukaryotic mRNAs ... Cap Analog for a portion of ... vitro transcription reaction results in the ...
... Orbital Shakers have the durability ... stacked 3-high, and the uniformity ... "soft shake" applications. Heavily ... systems, our stackers are designed ...
Biology Products: